The PATHWAY HER2 (4B5) test is now FDA-approved to assess HER2-ultralow status in metastatic breast cancer, expanding its ...

The FDA has approved a companion diagnostic to determine if patients with HR-positive, HER2-ultralow metastatic breast cancer are eligible for T-DXd treatment.

Quattro Financial Advisors LLC lowered its stake in shares of AstraZeneca PLC (NASDAQ:AZN – Free Report) by 7.7% during the ...

Avitas Wealth Management LLC lessened its holdings in shares of AstraZeneca PLC (NASDAQ:AZN – Free Report) by 39.2% in the ...

Roche has secured a new FDA approval for its first companion diagnostic test aimed at identifying breast cancer patients with ...

The FDA has approved an expanded label for Roche’s PATHWAY anti-HER2/neu (4B5) Rabbit Monoclonal Primary Antibody test, which ...

PHARMACEUTICAL giant AstraZeneca has scrapped plans for a £450m (US$559m) upgrade to its vaccine manufacturing facility in ...

AstraZeneca’s Imfinzi (durvalumab) has received a positive recommendation from the European Medicines Agency’s Committee for Medicinal Produc ...

Pfizer has ended development of a B7-H4-directed antibody-drug conjugate (ADC), triggering a $1 billion impairment charge. | ...

Imfinzi recommended for approval in European Union for the treat of adults with limited-stage small cell lung cancer ...

The U.S. Food and Drug Administration has approved Enhertu (trastuzumab deruxtecan) for the treatment of adult patients with ...

January's FDA oncology approvals offer new treatment options for breast cancer, mantle cell lymphoma, and other malignancies.